09.12.2009 • News

Solvay Q1 Operating Tops Forecast

Solvay posted a 53 % fall in recurring Q1 operating profit, beating estimates, but said full-year operating profit would be below 2008. Recurring earnings before interest and tax (REBIT) fell to €142 million. Last year, the company reported €300 million in Q1 REBIT. Solvay said the pharmaceuticals unit would achieve in 2009 a higher operating result than last year, but conditions remained difficult for chemicals and plastics and visibility was limited.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read